Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy

The study aimed at identifying patient-specific dosimetric and nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after (131)I-tositumomab radioimmunotherapy for potential use in treatment planning. METHODS: Tumor-absorbed dose measures were estimated for 130 tumors in 39 rela...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Nucl Med
Prif Awduron: Dewaraja, Yuni K., Schipper, Matthew J., Shen, Jincheng, Smith, Lauren B., Murgic, Jure, Savas, Hatice, Youssef, Ehab, Regan, Denise, Wilderman, Scott J., Roberson, Peter L., Kaminski, Mark S., Avram, Anca M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2014
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237694/
https://ncbi.nlm.nih.gov/pubmed/24842891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.113.136044
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg